A day before the release of highly anticipated detailed risk-benefit data for osteoporosis drug denosumab, Amgen Inc. said it was divesting three marketed products to Swedish specialty pharma firm Biovitrum AB in exchange for $130 million up front, plus potential sales milestones and royalties down the road. (BioWorld Today)

ATLANTA - There's no question that "antibodies have come a long way in the last 20 to 25 years," said Fritz Rudert, general manager of German consulting firm FHR Consult and moderator of a panel on antibodies at the first annual BioPharm America conference. (BioWorld Financial Watch)

ProMetic Life Sciences Inc. entered a potential $295 million licensing agreement with Abraxis BioScience to develop four products targeting undisclosed underserved medical conditions on a worldwide basis, excluding China and Taiwan. (BioWorld Today)